OncoTherapy Science <4564.T>-2008/09 parent

May 18 (Reuters) -

ONCOTHERAPY SCIENCE INC

PARENT-ONLY FINANCIAL HIGHLIGHTS

(in billions of yen unless specified)

Year ended Year ended Year to

Mar 31, 2009 Mar 31, 2008 Mar 31, 2010

LATEST YEAR-AGO COMPANY

RESULTS RESULTS FORECASTS
Sales 3.33 1.97 4.30

(+68.7 pct) (+145.2 pct) (+29.2%)
Operating prft 167 mln loss 237 mln prft 250 mln

(+49.2%)
Recurring prft 251 mln loss 183 mln prft 294 mln

(+17.3%)
Net prft 213 mln loss 306 mln prft 250 mln

(+17.3%)
EPS prft Y1,063.47 loss Y1,552.41 prft Y1,236.97
Diluted
EPS Y916.40
Annual div nil nil nil
-Q4 div nil nil nil

NOTE - OncoTherapy Science Inc engages in R&D of cancer drugs.

If there is no Q1 or Q3 dividend, Q2 will in most cases
correspond to the first-half dividend and Q4 to the second-half
dividend announced before a new corporate law in 2006 allowed
companies to pay and report dividends on a quarterly basis.

For latest earnings estimates made by Toyo Keizai, please
double click on 4564.TK1.